- Home
- HOPE vs SYRE Comparison
HOPE vs SYRE Comparison
Compare HOPE & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOPE
- SYRE
- Stock Information
- Founded
- HOPE 1986
- SYRE 2013
- Country
- HOPE United States
- SYRE United States
- Employees
- HOPE N/A
- SYRE N/A
- Industry
- HOPE Major Banks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HOPE Finance
- SYRE Health Care
- Exchange
- HOPE Nasdaq
- SYRE Nasdaq
- Market Cap
- HOPE 1.3B
- SYRE 1.1B
- IPO Year
- HOPE 1996
- SYRE 2016
- Fundamental
- Price
- HOPE $10.56
- SYRE $16.86
- Analyst Decision
- HOPE Buy
- SYRE Buy
- Analyst Count
- HOPE 2
- SYRE 5
- Target Price
- HOPE $13.25
- SYRE $55.00
- AVG Volume (30 Days)
- HOPE 1.1M
- SYRE 516.1K
- Earning Date
- HOPE 07-22-2025
- SYRE 08-05-2025
- Dividend Yield
- HOPE 5.30%
- SYRE N/A
- EPS Growth
- HOPE N/A
- SYRE N/A
- EPS
- HOPE 0.34
- SYRE N/A
- Revenue
- HOPE $412,692,000.00
- SYRE N/A
- Revenue This Year
- HOPE $19.82
- SYRE N/A
- Revenue Next Year
- HOPE $9.95
- SYRE N/A
- P/E Ratio
- HOPE $31.03
- SYRE N/A
- Revenue Growth
- HOPE N/A
- SYRE N/A
- 52 Week Low
- HOPE $8.83
- SYRE $10.91
- 52 Week High
- HOPE $14.54
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- HOPE 50.47
- SYRE 53.78
- Support Level
- HOPE $9.83
- SYRE $14.72
- Resistance Level
- HOPE $10.63
- SYRE $17.42
- Average True Range (ATR)
- HOPE 0.23
- SYRE 0.94
- MACD
- HOPE 0.04
- SYRE -0.01
- Stochastic Oscillator
- HOPE 84.87
- SYRE 65.33
About HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.